Siltuximab
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research[1][2][3].
Product Specifications
CAS Number
541502-14-1
Product Name Alternative
CNTO-328
UNSPSC
12352203
Target
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/siltuximab.html
Purity
99.0
Solubility
H2O
Smiles
[Siltuximab]
Molecular Weight
(144.98 kDa)
References & Citations
[1]Karkera J, et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate. 2011 Sep 15;71 (13) :1455-65.|[2]Khan FA, et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax. 2021 Sep;76 (9) :907-919. doi: 10.1136/thoraxjnl-2020-215266. Epub 2021 Feb 12.|[3]Song L, et al. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J Thorac Oncol. 2014 Jul;9 (7) :974-982.|[4]Casneuf T, et al. Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer. Breast Cancer (Dove Med Press) . 2016 Feb 3;8:13-27.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC740262-100 1x 100 µL
Human Lambda Light Chain (HP6054), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details